Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea

Vaccine

Volumn 29, Issue 3, 2011, Pages 523-527

  Cheong, Hee Jin ^a   Song, Joon Young ^a   Heo, Jung Yeon ^a   Noh, Ji Yun ^a   Choi, Won Suk ^a   Park, Dae Won ^a   Wie, Seong Heon ^b   Kim, Woo Joo ^a  

^a Korea University College of Medicine   (South Korea)

^b The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

2009 H1N1; Immunogenicity; Influenza; Vaccination

Indexed keywords

HEMAGGLUTININ;

ADULT; AGED; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; DRUG FEVER; DRUG FORMULATION; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION; HEMAGGLUTINATION TEST; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE REDNESS; INJECTION SITE SWELLING; INJECTION SITE TENDERNESS; KOREA; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SHIVERING; SIDE EFFECT; SWEATING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MIDDLE AGED; REPUBLIC OF KOREA; VACCINATION; VACCINES, INACTIVATED; VACCINES, SUBUNIT;

EID: 78650521372     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.060     Document Type: Article

References (16)

1. World Health Organization. DG statement following the meeting of the emergency committee [Internet]; June 11, 2009 [cited 2009 September 9]. Available from: http://www.who.int/csr/disease/swineflu/4th_meeting_ihr/en/index.html.
2. World Health Organization New influenza A (H1N1) virus: global epidemiological situation. Wkly Epidemiol Rec 2009, 84(June):249-257.
3. U.S. President's Council of Advisors on Science and Technology. Report to the president on U.S. preparations for 2009 - H1N1 influenza [Internet]. Washington, DC: Executive Office of the President, President's Council of Advisors on Science and Technology; 2009 [cited 2009 September 8]. Available from: http://www.whitehouse.gov/assets/documents/PCAST_H1N1_Report.pdf.
4. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. New Engl J Med 2006, 354:1343-1351.
5. Hannoun C., Megas F., Piercy J. Immunogenicity and protective efficacy of influenza vaccination. Virus Res 2004, 103(1-2):133-138.
6. Kendal AP, Pereira MS, Skehel JJ, editors. Concepts and procedures for laboratory based influenza surveillance. Geneva: Viral Disease Unit, World Health Organization; 1982. Available from URL: [accessed 28.01.10]. http://whqlibdoc.who.int/publications/1982/a86910_partA.pdf.
7. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on harmonisation of requirements for influenza vaccines (CPMP/BWP/214/96) [Internet]. London: The European Agency for the Evaluation of Medicinal Products; 1997. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003945.pdf.
8. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007. Available from URL: [accessed November 28, 2009]. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074775.htm.
9. Plennevaux E., Sheldon E., Blatter M., Reeves-Hoche M.K., Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010, 375:41-48.
10. Greenberg M.E., Lai M.H., Hartel G.F., Wichems C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. New Engl J Med 2009, 361:2405-2413.
11. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010, 375:56-66.
12. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. New Engl J Med 2009, 361:2424-2435.
13. Kim B.N., Kwak Y.G., Moon C.S., Kim Y.S., Kim E.S., Bae I.G., et al. Trend in age distribution of visitors to flu-clinics during the pandemic influenza (H1N1 2009). Infect Chemother 2010, 42:90-94. [Korean].
14. Zhu F.C., Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. New Engl J Med 2009, 361:2414-2423.
15. Zimmer S.M., Burke D.S. Historical perspective - emergence of influenza A (H1N1) viruses. New Engl J Med 2009, 361:279-285.
16. Palache A.M. Influenza vaccines. A reappraisal of their use. Drugs 1997, 54:841-856.